FCER2: Low affinity immunoglobulin epsilon Fc receptor
Low-affinity receptor for immunoglobulin E (IgE) and CR2/CD21.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on FCER2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Lumiliximab | Phase 2 | Biogen | Antibody | AntagonistImmunoglobulin epsilon Fc receptor antagonist | 0 |
- Abnormality of the skeletal system0.18
- Diabetes mellitus0.14
- B-cell chronic lymphocytic leukemia0.14
- Atopic eczema0.08
- Asthma0.08
- Childhood leukemia0.07
- Mantle cell lymphoma0.07
- Aicardi-Goutieres syndrome0.07
- Rheumatoid arthritis0.07
- Chronic obstructive pulmonary disease0.06
- Skin disorder0.06
- Malignant hyperthermia of anesthesia0.06
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2940, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P06734, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets